Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Britain Courts Anthropic Amid US Defense Department Dispute 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
AKRON, Ohio, Jan. 26, 2017 -- O2 RegenTech, a medical technology company focused on wound care solutions, has been awarded a $225,000 National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant to conduct research and development on its oxygenating wound dressing that enhances chronic wound healing. Additionally, the company received a $225,000 National Institutes of Health (NIH) Small Business Technology Transfer (STTR) grant and $150,000 from the Ohio Third Frontier (OTF) Technology Validation and Startup Fund (TVSF).
The three most important factors in wound healing are oxygen, moisture, and protection from bacteria to prevent infections. Currently, there are no wound treatments available that offer all three components at once, requiring patients to use a combination of different bandages, dressings, ointments, and other treatments. O2 RegenTech aims to make wound care simpler with its proprietary product, OXAID™, a treatment that provides all three important components to promote wound healing in one easy-to-use dressing.
“O2 RegenTech is extremely excited to receive the support of the NSF, the NIH, and the OTF,” said Dr. Andreas Inmann, President & CEO of O2 RegenTech. “This funding validates our approach and will be instrumental in moving our technology closer to regulatory submission and commercialization.”
About O2 RegenTech
O2 RegenTech LLC is a medical technology company focused on wound care solutions. The technology is protected by pending patents licensed from The University of Akron in Akron, OH. For more information: www.o2regentech.com.
Contact Information:
Andreas Inmann, PhD, MBA
President & CEO
(267) 231-8908
[email protected]
